New cancer drug shows promise in early trial
NCT ID NCT06238479
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and effective, and will involve about 490 participants over up to 4 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY4101174 (an antibody-drug conjugate targeting Nectin-4)
- What this could lead to
- If successful, this could lead to a new treatment option for several advanced cancers that have stopped responding to other therapies.
- What could go wrong
- This is an early Phase 1 trial, so the drug may not be effective or could have serious side effects. It is still being tested for the right dose and safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Austin Health
Heidelberg, 3084, Australia
-
CHU Strasbourg-Hautepierre
Strasbourg, 67098, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Emory University
Atlanta, Georgia, 30322, United States
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Virgen Del Rocio
Seville, 41013, Spain
-
Hunan Cancer Hospital
Changsha, 410013, China
-
Icon Cancer Centre Kurralta Park
Kurralta Park, 5037, Australia
-
Institut Jules Bordet
Anderlecht, 1070, Belgium
-
Institut Paoli-Calmettes
Marseille, 13273, France
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chūōku, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, 277-8577, Japan
-
Peking University First Hospital
Beijing, 100034, China
-
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
Shanghai East Hospital
Shanghai, 200433, China
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229-3307, United States
-
The Cancer Institute Hospital of JFCR
Kōtō City, 135-8550, Japan
-
UT Southwestern Medical Center
Dallas, Texas, 75390-8884, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can your own immune cells beat advanced cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?